Champions Oncology (CSBR) Proxy filing summary

Executive summary

• Annual Meeting scheduled for October 14, 2026, with record date set as August 21, 2026.

• Shareholders will vote on director elections, auditor ratification, executive compensation, frequency of say-on-pay votes, and a new equity incentive plan.

• Proxy materials are available online, and shareholders are encouraged to vote electronically or by mail.

Voting matters and shareholder proposals

• Election of seven director nominees for one-year terms.

• Ratification of EisnerAmper LLP as independent auditor for fiscal year ending April 30, 2027.

• Advisory vote on executive compensation (say-on-pay) and on the frequency of such votes, with board recommending every three years.

• Approval of the 2026 Equity Incentive Plan, authorizing new equity awards.

Board of directors and corporate governance

• Board consists of seven members, with five deemed independent under Nasdaq rules.

• Recent leadership changes: Robert Brainin became CEO in August 2025; Ronnie Morris transitioned to Chairman.

• Board met three times in fiscal 2026; all directors attended at least 75% of meetings.

• Committees include Audit, Compensation, and Nominating & Corporate Governance, all with independent members.

• Shareholders can communicate with the board via written correspondence.